scholarly journals Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection

2007 ◽  
Vol 196 (10) ◽  
pp. 1438-1446 ◽  
Author(s):  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Hpv Infection ◽  
Prophylactic Efficacy

scholarly journals An Integrative Review of the Influences on Decision-Making of Young People About Human Papillomavirus Vaccine

2018 ◽  
Vol 35 (1) ◽  
pp. 39-50
Author(s):  
Helen Sisson ◽  
Yvonne Wilkinson
Keyword(s):  
Decision Making ◽  
Human Papillomavirus ◽  
Parental Involvement ◽  
Health Care Providers ◽  
Hpv Vaccine ◽  
Hpv Infection ◽  
School Nurses ◽  
Human Papillomavirus Vaccine ◽  
Care Providers ◽  
To Receive

The human papillomavirus (HPV) vaccine is a key intervention in the prevention of HPV infection and associated cancers. This review emphasizes the importance of understanding what influences decision-making about this vaccine. Guided by the work of Whittemore and Knafl, and Pluye and Hong, we identified 25 studies, from which four prominent themes emerged: fear and risk, pain, parental involvement, and involvement of others. Fear of cervical cancer was a strong motivation to receive the vaccine, and the extent of parental involvement also had an impact on decision-making. Recommendations to receive the vaccine by health-care providers were also an important influence. School nurses are fundamental to the promotion and delivery of the HPV vaccine and should stress the significant role that it plays in the prevention of cancer. Additionally, school nurses should ensure that discussions about HPV infection and vaccine include parents where appropriate and should distinctly recommend vaccination to those eligible.

scholarly journals High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China

2021 ◽  
Vol 8 ◽  
Author(s):  
Ze-Hao Ye ◽  
Zhao-Zhen Liu ◽  
Si-Tong Cui ◽  
Zhen-Xing Chu ◽  
Yong-Jun Jiang ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Hpv Vaccine ◽  
Online Survey ◽  
Cost Effective ◽  
Hpv Infection ◽  
Human Papillomavirus Vaccine ◽  
Vaccine Acceptability ◽  
Cross Sectional ◽  
Sex With Men

Background: Despite the insupportable burden caused by the human papillomavirus (HPV) and high vaccine acceptability, vaccination programs are not currently available for men who have sex with men (MSM). We aimed to assess HPV infection by examining the willingness for vaccination among MSM and cost-effectiveness of the Chinese 2-valent HPV vaccine.Methods: We recruited MSM in Shenyang, China between July and December 2020 to conduct anal HPV testing and an online survey regarding HPV-related knowledge and vaccine acceptability. We performed a cost-effectiveness analysis to evaluate the incremental cost-effectiveness ratios (ICERs) of the Chinese 2-valent HPV vaccine.Results: A total of 234 participants completed the online survey; of those, 203 were successfully tested for HPV. The median age was 30 years [interquartile range (IQR): 23–38 years]. Most participants had at least undergraduate education (136/234, 58.1%). The acceptability rate for the free HPV vaccine was 57.7% (135/234). The prevalence of HPV types 16 and 18 was 14.9% (18/121) and 26.8% (22/82) in the willing and unwilling to vaccinate groups, respectively (P > 0.05). The prevalence of high-risk HPV among participants aged <30 and ≥50 years was 48.6 and 38.9%, respectively. Using the Chinese per capita gross domestic product (GDP) as a threshold, the Chinese 2-valent HPV vaccine would be a “very cost-effective” strategy, with an ICER value of USD 4,411. This evidence showed that the Chinese 2-valent HPV vaccine was more cost-effective than other imported vaccines.Conclusions: Targeted strategies should be utilized in MSM with different rates of vaccine acceptability. A pilot HPV vaccination program based on the Chinese 2-valent HPV vaccine for MSM is urgently warranted to reduce the burden of HPV and anal cancer.

Human papillomavirus (HPV) vaccine acceptance and perceived effectiveness, and HPV infection concern among young New Zealand university students

Sexual Health ◽  
2010 ◽  
Vol 7 (3) ◽  
pp. 394 ◽  
Author(s):  
Carol Chelimo ◽  
Trecia A. Wouldes ◽  
Linda D. Cameron
Keyword(s):  
Human Papillomavirus ◽  
Undergraduate Students ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Infection Risk ◽  
Vaccine Acceptance ◽  
Sexually Transmitted ◽  
Behavioural Characteristics

Two-hundred undergraduate students completed an anonymous questionnaire after viewing a human papillomavirus (HPV) vaccine television commercial. Eight-four percent of participants would accept a free HPV vaccine, whereas 47% were unconcerned about future personal HPV infection risk. Males were less likely to accept a free HPV vaccine and to be concerned about future personal HPV infection risk. Perceived HPV vaccine effectiveness was significantly greater among participants who had previously heard of the vaccine and who knew that HPV is sexually transmitted. More education on the role of sexual behavioural characteristics of both males and females in HPV transmission is necessary to promote awareness and concern of personal HPV infection risk and acceptance of HPV vaccination.

Review of Evidence and Recommendation for Human Papillomavirus (HPV) Vaccination of Canadian Males Over the Age of 26 Years

2020 ◽  
Vol 24 (3) ◽  
pp. 285-291 ◽  
Author(s):  
Alex Derstenfeld ◽  
Kyle Cullingham ◽  
Zhuo Cai Ran ◽  
Ivan V. Litvinov
Keyword(s):  
Human Papillomavirus ◽  
Sexually Transmitted Infection ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Older Men ◽  
Hpv Infection ◽  
Transmitted Infection ◽  
Vaccination Programs ◽  
Sexually Transmitted ◽  
Control And Prevention

Human papillomavirus (HPV) remains the most common sexually transmitted infection with a lifetime incidence of over 75%. Based on US data from the Centers for Disease Control and Prevention (CDC), 64% of invasive HPV-associated cancers are attributable to HPV 16 or 18 (65% for females; 63% males) and may be prevented by vaccination with either the quadrivalent or nonavalent HPV vaccine. Public HPV vaccination programs are now the norm for women aged 9-45 years and men aged 9-26 years in Canada. Yet, only recently have guidelines begun to consider vaccination of men older than 26 years of age. There now exist compelling reasons to recommend vaccination against HPV amongst males >26 years of age. Recognizing that the risks posed by HPV infection persist beyond 26 years of age, that the vaccination of men aged 26-45 years with HPV vaccine confers immunogenicity at levels demonstrably efficacious against HPV-related diseases, and that the Food and Drug Administration recently expanded the HPV vaccination to include older men, it is argued that HPV vaccination in men older than 26 years of age should be routinely recommended.

scholarly journals HPV AND HEAD NECK MALIGNANCIES – ROLE OF VACCINATION

2018 ◽  
Vol VOLUME 6 (VOLUME 6 NUMBER 2 DECEMBER 2018) ◽  
pp. 22-26
Author(s):  
Sumit Sharma
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Hpv Infection ◽  
Sexual Contact ◽  
Dna Virus ◽  
Modes Of Transmission ◽  
Male Sex ◽  
Head Neck

Human papillomavirus is a DNA virus from the papillomavirus family and it not only causes genital and anal cancers, but also causes a subset of head and neck squamous cell carcinoma. It has both sexual and non sexual modes of transmission, former being predominant. Other factors associates with higher risk of HPV induced carcinogenesis are -- Smoking and HIV-infection, male sex and older age. Vaccines are available to prevent HPV infection and are to be given to boys and girls between 14-26 years of age preferably before first sexual contact, and if you already have an HPV infection, getting the HPV vaccine can’t treat it, but it can protect you from getting other types of HPV infections.

scholarly journals Prevalence, Incidence, and Clearance of Human Papillomavirus Types Covered by Current Vaccines in Men With Human Immunodeficiency Virus in the SUN Study

2019 ◽  
Vol 222 (2) ◽  
pp. 234-242 ◽  
Author(s):  
Pragna Patel ◽  
Tim Bush ◽  
Lois Conley ◽  
Elizabeth R Unger ◽  
Teresa M Darragh ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Papillomavirus ◽  
High Risk ◽  
Hpv Vaccine ◽  
Hpv Infection ◽  
Abnormal Cytology ◽  
Immunodeficiency Virus ◽  
Vaccine Impact ◽  
Sex With Men ◽  
High Risk Hpv

Abstract Background High-risk anal human papillomavirus (HPV) infection is prevalent among men living with human immunodeficiency virus (HIV); the association between 9-valent (9v) high-risk HPV (HR-HPV) vaccine types and abnormal cytology has not been well characterized. Methods We followed a prospective cohort study of persons with HIV at 7 HIV clinics in 4 US cities from March 2004 through June 2012. Annually, providers collected separate anal swabs for HPV detection and cytopathologic examination. Among men, we examined prevalence, incidence, and clearance of 9v HR-HPV vaccine types, compared with other HR types, and associations with abnormal cytology to assess potential vaccine impact. Results Baseline prevalence of any anal 9v HR-HPV type among men who have sex with men (MSM) and men who have sex with women (MSW) was 74% and 25% (P < .001), respectively. Among 299 MSM, abnormal cytology was detected in 161 (54%) MSM and was associated with the presence of any 9v HR-HPV (relative risk [RR], 1.8 [95% confidence interval {CI}, 1.3–2.6]; P < .001). Among 61 MSW, abnormal anal cytology was detected in 12 (20%) and was associated with the presence of any 9v HR-HPV (RR, 4.3 [95% CI, 1.6–11.5]; P < .001). Conclusions Among men with HIV, the prevalence of the 7 HR-HPV types in the 9v vaccine was high and was associated with abnormal cytology. These findings indicate that men with HIV could benefit from prophylactic administration of the 9v HPV vaccine.

scholarly journals Positivity and prevalence of human papillomavirus among a large population of women in southeastern China

2019 ◽  
Vol 47 (12) ◽  
pp. 6171-6181 ◽  
Author(s):  
Sudong Liu ◽  
Xiaodong Gu ◽  
Ruiqiang Weng ◽  
Jing Liu ◽  
Zhixiong Zhong
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Large Population ◽  
Hpv Infection ◽  
Southeastern China ◽  
Screening Programs ◽  
Specific Distribution ◽  
Luminex Technology ◽  
Hpv Genotypes

Objective To formulate strategies for prevention of cervical cancer, we investigated the prevalence of human papillomavirus (HPV) infection and the age-specific distribution among female participants in southeastern China. Methods From January 2016 to July 2018, 36,871 women from Meizhou People’s Hospital (Huangtang Hospital), Meizhou Hospital Affiliated to Sun Yat-sen University were enrolled in this prospective study. HPV genotypes were detected using Luminex technology. Results HPV infection was observed in 18.34% of the participants, and 79.98% were infected with high-risk HPVs. The five most prevalent genotypes were HPV52 (18.18%), HPV16 (16.06%), HPV58 (11.37%), HPV53 (8.82%), and HPV39 (6.42%). The 9-valent HPV vaccine efficiently reduced the HPV infection rate by more than 10%, which is twofold the rate of other vaccines. Most HPV infections were observed in women age 40 to 49 years, and those age 30 to 59 years accounted for 79.62% of positive patients. Conclusion Our findings regarding HPV genotypes and the age-specific distribution of HPV infection in the study area will contribute to the development of cervical cancer screening programs and vaccine strategies.

scholarly journals Acceptability of the Human Papillomavirus Vaccine Among Urban Adolescent Males

2012 ◽  
Vol 7 (1) ◽  
pp. 27-36 ◽  
Author(s):  
Baudelio Gutierrez ◽  
Anthony Leung ◽  
Kevin Trimell Jones ◽  
Peter Smith ◽  
Randee Silverman ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Adolescent And Young Adult ◽  
Human Papillomavirus Vaccine ◽  
Adult Males ◽  
Urban Adolescent ◽  
Increased Risk ◽  
Sex With Men

The human papillomavirus (HPV) vaccine was recently approved for use in males. Certain groups, such as men who have sex with men (MSM), are at increased risk of HPV infection. The purpose of the study was to understand perceptions of HPV and the vaccine among adolescent and young adult males, both heterosexual and MSM. Seventy-six males (45 heterosexual, 31 MSM) completed a questionnaire and participated in a focus group. Overall, 42% had heard of HPV and 39% had heard of the HPV vaccine. Males had moderate to favorable attitudes toward vaccination, although intentions to vaccinate were more neutral. MSM were more knowledgeable, aware, and in control of the decision to vaccinate than heterosexual males. Increasing awareness and knowledge about HPV and the vaccine may be necessary to encourage vaccination; certain subgroups of males may be more receptive to HPV vaccination than others.

scholarly journals Perceptions of Human Papillomavirus (HPV) infection and acceptability of HPV vaccine among men attending a sexual health clinic differ according to sexual orientation

2016 ◽  
Vol 12 (6) ◽  
pp. 1542-1550 ◽  
Author(s):  
Massimo Giuliani ◽  
Maria Fenicia Vescio ◽  
Maria Gabriella Donà ◽  
Alessandra Latini ◽  
Mirko Frasca ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Sexual Orientation ◽  
Sexual Health ◽  
Hpv Vaccine ◽  
Hpv Infection ◽  
Health Clinic
Sign in / Sign up

Export Citation Format

Share Document